ES491998A0 - Un procedimiento para preparar compuestos aromaticos susti- tuidos - Google Patents

Un procedimiento para preparar compuestos aromaticos susti- tuidos

Info

Publication number
ES491998A0
ES491998A0 ES491998A ES491998A ES491998A0 ES 491998 A0 ES491998 A0 ES 491998A0 ES 491998 A ES491998 A ES 491998A ES 491998 A ES491998 A ES 491998A ES 491998 A0 ES491998 A0 ES 491998A0
Authority
ES
Spain
Prior art keywords
procedure
aromatic compounds
substituted aromatic
preparing substituted
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES491998A
Other languages
English (en)
Other versions
ES8104993A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES491998(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of ES491998A0 publication Critical patent/ES491998A0/es
Publication of ES8104993A1 publication Critical patent/ES8104993A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES491998A 1979-06-01 1980-05-30 Un procedimiento para preparar compuestos aromaticos susti- tuidos Expired ES8104993A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01

Publications (2)

Publication Number Publication Date
ES491998A0 true ES491998A0 (es) 1981-05-16
ES8104993A1 ES8104993A1 (es) 1981-05-16

Family

ID=10505597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES491998A Expired ES8104993A1 (es) 1979-06-01 1980-05-30 Un procedimiento para preparar compuestos aromaticos susti- tuidos

Country Status (30)

Country Link
US (2) US4486354A (es)
EP (2) EP0021121B1 (es)
JP (2) JPS5625169A (es)
AR (1) AR227521A1 (es)
AT (1) AT370097B (es)
AU (2) AU530999B2 (es)
BG (1) BG60427B2 (es)
CA (1) CA1112643A (es)
CS (1) CS234018B2 (es)
CZ (1) CZ384891A3 (es)
DD (1) DD151309A5 (es)
DK (1) DK153787C (es)
ES (1) ES8104993A1 (es)
FI (1) FI67844C (es)
GE (1) GEP19960470B (es)
GR (1) GR68380B (es)
HU (1) HU182086B (es)
IE (1) IE49823B1 (es)
IL (1) IL60201A (es)
IT (1) IT1147087B (es)
MX (1) MX9202962A (es)
MY (1) MY8500062A (es)
NL (1) NL950007I2 (es)
NZ (1) NZ193890A (es)
PL (1) PL124029B1 (es)
SU (1) SU1055331A3 (es)
UA (1) UA5576A1 (es)
YU (1) YU145680A (es)
ZA (1) ZA803250B (es)
ZW (1) ZW12980A1 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1145308B (it) * 1979-08-16 1986-11-05 Wellcome Found Composti aromatici sostituiti
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
AU688729B2 (en) * 1992-06-12 1998-03-19 Wellcome Foundation Limited, The Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
IN183150B (es) * 1998-12-14 1999-09-25 Torrent Pharmaceuticals Ltd
CZ20011949A3 (cs) * 1998-12-14 2001-09-12 Torrent Pharmacauticals Ltd Zlepšený způsob výroby 3,5-diamino-6-(2,3-dichlorfenyl)-1,2,4-triazinu
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
WO2000061188A1 (en) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
WO2001049669A1 (en) * 2000-01-03 2001-07-12 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
HRP20030419A2 (en) 2000-11-30 2004-08-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors
IL155704A0 (en) 2000-11-30 2003-11-23 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors
IL157608A0 (en) * 2001-02-27 2004-03-28 Teva Pharma New crystal forms of lamotrigine and processes for their preparations
SI1423168T1 (sl) 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003234240A1 (en) * 2002-04-23 2003-11-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
EP1603889A1 (en) * 2003-03-17 2005-12-14 Hetero Drugs Limited Novel crystalline forms of lamotrigine
US7504516B2 (en) 2003-03-27 2009-03-17 Hetero Drugs Limited Crystalline forms of candesartan cilexetil
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CA2553291A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
US20080096965A1 (en) * 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
PL1931335T3 (pl) * 2005-09-23 2010-07-30 Janssen Pharmaceutica Nv Modulatory heksahydrocyklooktylopirazolokannabinoidowe
US7790718B2 (en) 2005-09-23 2010-09-07 Janssen Pharmaceutica Nv Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
HRP20120159T1 (hr) * 2005-09-23 2012-03-31 Janssen Pharmaceutica Nv Modulatori heksahidro-cikloheptapirazol kanabinoida
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2007092456A2 (en) * 2006-02-03 2007-08-16 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
WO2007095513A1 (en) * 2006-02-14 2007-08-23 Janssen Pharmaceutica, Nv Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
ATE452125T1 (de) * 2006-05-31 2010-01-15 Calaire Chimie Sas Verfahren zur herstellung von lamotrigin und dessen zwischenprodukt 2,3-dichlorbenzoylchlorid
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CN101506178A (zh) * 2006-08-14 2009-08-12 隆沙有限公司 制备拉莫三嗪的方法
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
JP5656980B2 (ja) 2009-05-13 2015-01-21 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー含有の置換芳香族トリアジン化合物
US20100297195A1 (en) 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
WO2015092819A2 (en) * 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
WO2016198878A1 (en) 2015-06-12 2016-12-15 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
LT3554490T (lt) 2016-12-16 2022-04-25 Idorsia Pharmaceuticals Ltd Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
GB2641294A (en) 2024-05-24 2025-11-26 Novumgen Ltd An orodispersible tablet of Lamotrigine and its process of preparation
US12605388B2 (en) * 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (es) * 1964-05-05
BE722109A (es) * 1967-10-12 1969-04-10
GB1223491A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
IT1145308B (it) * 1979-08-16 1986-11-05 Wellcome Found Composti aromatici sostituiti

Also Published As

Publication number Publication date
CZ384891A3 (en) 1993-10-13
FI801758A7 (fi) 1980-12-02
ZA803250B (en) 1982-01-27
YU145680A (en) 1983-02-28
IT1147087B (it) 1986-11-19
NZ193890A (en) 1984-07-06
JPS5625169A (en) 1981-03-10
HU182086B (en) 1983-12-28
EP0059987A1 (en) 1982-09-15
UA5576A1 (uk) 1994-12-28
IL60201A (en) 1984-05-31
EP0021121A1 (en) 1981-01-07
CS234018B2 (en) 1985-03-14
AU5890680A (en) 1980-12-04
IE49823B1 (en) 1985-12-25
PL124029B1 (en) 1982-12-31
MY8500062A (en) 1985-12-31
DK153787C (da) 1989-01-16
FI67844B (fi) 1985-02-28
EP0021121B1 (en) 1983-05-11
ZW12980A1 (en) 1982-01-06
JPH0144179B2 (es) 1989-09-26
NL950007I2 (nl) 1997-02-03
ATA289680A (de) 1982-07-15
MX9202962A (es) 1992-07-01
BG60427B2 (bg) 1995-03-31
JPH0144706B2 (es) 1989-09-29
AR227521A1 (es) 1982-11-15
DK153787B (da) 1988-09-05
AU566870B2 (en) 1987-11-05
DK233880A (da) 1980-12-02
EP0059987B1 (en) 1985-08-14
PL224633A1 (es) 1981-02-13
IT8048848A0 (it) 1980-05-30
GR68380B (es) 1981-12-28
DD151309A5 (de) 1981-10-14
SU1055331A3 (ru) 1983-11-15
NL950007I1 (nl) 1995-06-16
CA1112643A (en) 1981-11-17
GEP19960470B (en) 1996-08-29
FI67844C (fi) 1985-06-10
IL60201A0 (en) 1980-07-31
US4486354A (en) 1984-12-04
AT370097B (de) 1983-02-25
IE801126L (en) 1980-12-01
JPS6133163A (ja) 1986-02-17
US4602017A (en) 1986-07-22
AU530999B2 (en) 1983-08-04
ES8104993A1 (es) 1981-05-16

Similar Documents

Publication Publication Date Title
ES496948A0 (es) Un procedimiento para preparar compuestos de cefem
ES495376A0 (es) Un procedimiento para preparar un compuesto de 1,8-naftiri- dina
ES489222A0 (es) Un procedimiento para preparar un compuesto de guanidinotia-zol
ES490503A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES493061A0 (es) Un procedimiento para preparar un lipopolisacarido
ES490166A0 (es) Un procedimiento para preparar mercaptoacildipeptidos
ES489629A0 (es) Procedimiento para preparar un derivado de benzamida
ES497846A0 (es) Procedimiento para preparar aldehidos aromaticos
ES492001A0 (es) Un procedimiento para preparar compuestos de cefem
ES497303A0 (es) Un procedimiento para preparar 9-aminoalquilfluorenos
ES503134A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES494459A0 (es) Un procedimiento para preparar cetoximinoeteres
ES505498A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES505496A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES493798A0 (es) Un procedimiento para preparar 7-alcoxicarbonil-6,8-dime- til-4-hidroximetil-1-ftalazona
ES494629A0 (es) Un procedimiento para preparar compuestos de tiofosfonato nosimetricos
ES494098A0 (es) Un procedimiento para preparar eteres difenilicos sustitui- dos
ES496859A0 (es) Un procedimiento para preparar derivados de halofenil-piri- dilalilamina
ES494226A0 (es) Procedimiento para preparar un 1,2,4-triazol-3-tiol
ES488808A0 (es) Un procedimiento para preparar derivados de fenotiazina
ES491752A0 (es) Un procedimiento para la preparacion de nuevos polihaloquinoxalin-sulfonatos de haloalquilo.
ES505714A0 (es) Un procedimiento para preparar compuestos de cefem
ES498168A0 (es) Un procedimiento para preparar alcohilfosfonoditioato de al-cohilo
ES492210A0 (es) Un procedimiento para preparar b-cloroalanina
ES494328A0 (es) Un procedimiento para preparar 5-halogenopirimidina